Micreos, a Wageningen, The Netherlands-based developer of phage technology for targeted control of bacteria, has raised additional capital.
Altria Ventures, the strategic investment arm of Altria Group, has acquired a 5% stake in the company.
Micreos intends to use the funding, whose amount was not disclosed, to accelerate the growth of its phage business.
Led by CEO Mark Offerhaus, the company develops phage-based products against dangerous bacteria focusing on antibacterial solutions for human health and food safety.
FinSMEs
23/05/2012